IRIX - イリデックス (IRIDEX Corporation) イリデックス

 IRIXのチャート


 IRIXの企業情報

symbol IRIx
会社名 IRIDEX Corp. (イリデックス)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Electromedical_Electrotherapeutic Apparatus  
業種 先端医療機器_テクノロジ―   医療関連(Health Care)
概要 事業概要 イリデックス(IRIDEX Corporation)は眼科学における目の疾患の治療用の治療ベースのレーザーシステム、送達デバイス及び消耗器具のグローバルなプロバイダー。同社は主に眼科に集中する。同社の眼科治療商品は主に直販の方式で米国内に販売されて、100カ国以上における約70の独立系代理販売業者を介して国際的に販売される。同社の眼科治療商品は「IQ」と「OcuLight」レーザーシステム、消耗品、及びサービスと支援業務を含む。同社の「IQ」製品群は「IQ 532」、「IQ 577」と「IQ 810」のレーザー光凝固システムを含み、「OcuLight」商品は「OcuLight TX」、「OcuLight Symphony」(レーザー・デリバリー・システム)、「OcuLight SL」、「OcuLight SLx」、「OcuLight GL」及び「OcuLight GLx」のレーザー光凝固システムを含む。平成24年2月、同社はCutera Inc.に美容事業を譲渡した。   イリデックスは医療用レ―ザ―システムを提供する米国企業。眼疾患治療に使用されるレ―ザ―システム、送達デバイス及び消耗器具類などを開発、製造。糖尿病性網膜症、緑内障、加齢性黄斑変性症などの視力を脅かす眼の疾患を対象とする。販売代理店を通じて、世界的に製品を販売。本社はカリフォルニア州。   Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company's proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex's current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries.
本社所在地 1212 Terra Bella Avenue Mountain View CA 94043-1824 USA
代表者氏名 William M. Moore ウィリアム・M・ムーア
代表者役職名 Chairman of the Board Interim President and Chief Executive Officer
電話番号 +1 650-940-4700
設立年月日 32540
市場名 NASDAQ National Market System
ipoyear 1996年
従業員数 154人
url www.iridex.com
nasdaq_url https://www.nasdaq.com/symbol/irix
adr_tso
EBITDA EBITDA(百万ドル) -14.49200
終値(lastsale) 5.925
時価総額(marketcap) 69110260.575
時価総額 時価総額(百万ドル) 69.31863
売上高 売上高(百万ドル) 40.92100
企業価値(EV) 企業価値(EV)(百万ドル) 53.27363
当期純利益 当期純利益(百万ドル) -15.13400
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 IRIDEX Corporation revenues decreased 3% to $19.8M. Net loss increased 49% to $6.9M. Revenues reflect United States segment decrease of 14% to $10M Asia/Pacific Rim segment decrease of 2% to $3.9M. Higher net loss reflects Selling/General/Admin. Expense increase of 26% to $8M (expense) Selling expenses increase of 25% to $4.4M (expense).

 IRIXのテクニカル分析


 IRIXのニュース

   Iridex''s Cyclo G6 platform for treating glaucoma gets regulatory clearance in China  2022/06/14 14:02:34 Seeking Alpha
Iridex (IRIX) on Tuesday said it had got Chinese regulatory clearance to market and sell its Cyclo G6 platform for the treatment of glaucoma diseases.IRIX and its distribution…
   Iridex Obtains Regulatory Clearance for Cyclo G6® Glaucoma Platform in China  2022/06/14 13:21:00 GlobeNewswire
MOUNTAIN VIEW, Calif., June 14, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced that it has received regulatory clearance to market and sell its Cyclo G6 ® platform for the treatment of glaucoma diseases in China by its National Medical Products Administration (NMPA). In accordance with the clearance, Iridex and distribution partners Topcon and Clinico will launch the Cyclo G6 system and related probes in China beginning in the third quarter of 2022.
   Iridex Obtains Regulatory Clearance for Cyclo G6 Glaucoma Platform in China  2022/06/14 13:21:00 Wallstreet:Online
MOUNTAIN VIEW, Calif., June 14, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced that it has received regulatory clearance to market and sell its Cyclo G6 platform for the treatment of glaucoma diseases in China by its National Medical Products Administration
   Rate - IRIDEX Stock Rating Upgraded by Zacks Investment Research  2022/06/02 06:09:08 Business Mag
IRIDEX was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Thursday, Zacks.com reports. According to Zacks…
   IRIDEX Corporation''s (IRIX) CEO David Bruce on Q1 2022 Results - Earnings Call Transcript  2022/05/13 02:06:05 Seeking Alpha
IRIDEX Corporation (NASDAQ:NASDAQ:IRIX) Q1 2022 Earnings Conference Call May 12, 2022 5:00 PM ET Company Participants David Bruce – Chief Executive Officer Hunter Cabi – Investor Relations…
   Rate - IRIDEX Stock Rating Upgraded by Zacks Investment Research  2022/06/02 06:09:08 Business Mag
IRIDEX was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Thursday, Zacks.com reports. According to Zacks…
   IRIDEX Corporation''s (IRIX) CEO David Bruce on Q1 2022 Results - Earnings Call Transcript  2022/05/13 02:06:05 Seeking Alpha
IRIDEX Corporation (NASDAQ:NASDAQ:IRIX) Q1 2022 Earnings Conference Call May 12, 2022 5:00 PM ET Company Participants David Bruce – Chief Executive Officer Hunter Cabi – Investor Relations…
   IRIDEX GAAP EPS of -$0.15 beats by $0.01, revenue of $13.39M misses by $0.02M  2022/05/12 20:27:42 Seeking Alpha
IRIDEX press release (IRIX): Q1 GAAP EPS of -$0.15 beats by $0.01.Revenue of $13.39M (+12.0% Y/Y) misses by $0.02M.Guidance for Full Year 2022:Total revenue for the full year…
   Iridex Announces First Quarter 2022 Financial Results  2022/05/12 20:05:00 GlobeNewswire
Achieved Record First Quarter Revenue Achieved Record First Quarter Revenue
   Iridex to Report First Quarter 2022 Financial Results on May 12, 2022  2022/04/28 20:05:00 GlobeNewswire
MOUNTAIN VIEW, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the first quarter of 2022 after the close of trading on Thursday, May 12, 2022. The Company’s management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET.
   IRIDEX (NASDAQ:IRIX) Downgraded by TheStreet to D+  2021/12/21 16:02:42 Dakota Financial News
TheStreet downgraded shares of IRIDEX (NASDAQ:IRIX) from a c- rating to a d+ rating in a research note released on Friday, TheStreetRatingsTable reports. IRIDEX stock opened at $5.66 on Friday. The stock has a fifty day moving average of $7.26 and a two-hundred day moving average of $7.18. The company has a market capitalization of []
   Cosmetic Surgery Equipment Market Size 2021 By Trends Evaluation Forecast to 2027 Candela Medical, Cutera, Lumenis, Iridex Corp, Solta Medical, Medtronic  2021/12/13 10:45:43 OpenPR
The Global Cosmetic Surgery Equipment Market Report 2021 to 2027 could be a fundamental examination of the global analysis. Trending innovation, advertise drivers, sectional declination, analysis measurements, advertise forecasts, manufacturers, and hardware merchants are all included within the substance. The
   Laser Medical Devices Market Development History and Business Outlook 2027 BIOLASE, Philips, IRIDEX Corporation, LISA Laser USA, Alma Laser  2021/12/13 09:48:07 OpenPR
The Global Laser Medical Devices Market Report 2021 to 2027 could be a fundamental examination of the global analysis. Trending innovation, advertise drivers, sectional declination, analysis measurements, advertise forecasts, manufacturers, and hardware merchants are all included within the substance. The
   Zacks: Brokerages Anticipate IRIDEX Co. (NASDAQ:IRIX) Will Announce Earnings of -$0.11 Per Share  2021/12/11 21:46:42 Transcript Daily
Brokerages expect that IRIDEX Co. (NASDAQ:IRIX) will report earnings per share (EPS) of ($0.11) for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for IRIDEXs earnings. IRIDEX posted earnings per share of ($0.01) during the same quarter last year, which would indicate a negative year-over-year growth rate of 1,000%. The []
   $14.01 Million in Sales Expected for IRIDEX Co. (NASDAQ:IRIX) This Quarter  2021/12/11 21:46:42 Dakota Financial News
Wall Street analysts expect IRIDEX Co. (NASDAQ:IRIX) to announce $14.01 million in sales for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for IRIDEXs earnings, with the highest sales estimate coming in at $14.20 million and the lowest estimate coming in at $13.83 million. IRIDEX posted sales of $12.30 million during []

 関連キーワード  (先端医療機器_テクノロジ― 米国株 イリデックス IRIX IRIDEX Corporation)

医療で使われる機器のこと。レントゲン装置やからだの断面を画像化できるMRI(磁気共鳴画像)装置など高機能機器を含め数多くの種類がある。医療現場で使われるため、正確で精密である点などが求められる。医療機器への需要は着実に高まっており、電機メーカーなどからの進出も進んでいる。

 twitter  (公式ツイッターやCEOツイッターなど)